We sequenced 2,000 bp of the putative promoter region. The major SLE-prone mouse strains (NZB, BXSB, SB/Le and MRL) and NOD mice all shared a common Fcgr2 haplotype, characterised by a number of promoter alterations largely confined to the 250 bp immediately upstream of the start codon, and previously described in the NOD mouse [14] . The major one was a 13 bp deletion interrupting two putative transcription factor binding sites, an AP4 site and an S box ( Figure 1 and see Supplementary material). Control strains shared the 'normal' haplotype, and the NZW mouse had features of both ( Figure 1 ). The 129/Sv (and 129/Ola) mice are also prone to autoimmunity. For example, Lyn -/-mice made on the 129 background have substantially worse autoimmune disease than when they are backcrossed to C57BL/6 or BALB/c backgrounds (D.M. Tarlinton, personal communication) and the 129 background makes a contribution to the development of disease in the C1q -/-mouse (M. Botto, personal communication). We have termed this constellation of Fcgr2 promoter polymorphisms the 'autoimmune Fcgr2 promoter haplotype' (AIH). AIH strains include NZB, BXSB, SB/Le, MRL, NOD and 129. Sequence of the Fcgr2 promoter from autoimmune and control mouse strains. Control strains (con) include BALB/c, C57BL/6, C57BL/10 and DBA/2. AIH strains include NZB, BXSB, MRL, SB/Le, 129/Ola, 129/Sv and NOD. NZW mice share elements of both haplotypes. A dash indicates no difference from the control sequence and asterisks indicate deleted nucleotides. Nucleotides are numbered relative to the transcriptional start site (+1). Transcribed sequences are upper case. Consensus sequences for transcription factors are boxed and discussed further in the Supplementary material.
The AIH is associated with reduced expression of Fcγ γRII on macrophages and activated B cells
FcγRII expression was examined to determine if there was a defect associated with the AIH. There are two isoforms of FcγRII expressed on the cell surface in mice, FcγRIIb1 on B cells and FcγRIIb2 on cells including monocytes, macrophages, and mast cells [4, 5] . Peritoneal macrophages were stained with monoclonal antibody 2.4G2 (which recognises the identical extracellular domains of both FcγRIIb2 and FcγRIII on these cells [15] ). FcγRII/III levels on all AIH strains were reduced in comparison to control strains and NZW mice, and (NZB × NZW) F1 mice expressed intermediate levels (Figure 2a) . Levels of FcγRIIb1 (the only FcR recognised by 2.4G2 on B cells) were similar on resting splenic B cells of all of the strains studied, but fell progressively over time after activation in vitro in strains with the AIH (Figure 2b,d) . To confirm that the reduction in 2.4G2 staining seen on AIH strain macrophages was due to a reduction in FcγRII rather than FcγRIII, reduced expression of FcγRII was demonstrated by measuring mRNA specific for the various FcγRII isoforms using real-time RT-PCR. There was a marked reduction of Fcgr2 mRNA in AIH strain macrophages. No such reduction was seen in Fcgr3 mRNA, and the ratio of Further confirmation of the reduction in FcγRII expression on macrophages was obtained at the protein level ( Figure 3c ). A marked reduction in FcγRIIb2 was seen in NZB macrophages compared to control, particularly when assessed relative to FcγRIII. Thus, the observed reduction in 2.4G2 staining on macrophages is due to a reduction in FcγRIIb2, and the increase in the ratio of FcγRIII to FcγRII explains the functional effects outlined below.
Failure of Fcγ γRII-mediated negative regulation results in macrophage hyperactivity in AIH mice
To determine if the reduced expression of FcγRII in AIH mice has functional consequences, we measured the ability of macrophages to engulf opsonised sheep red blood cells (SRBCs). The cells were first haptenated with trinitrophenol (TNP) and then specific mouse anti-TNP antibodies were bound to opsonise the SRBCs by coating them with mouse antibody. The process of phagocytosis is dependent on activatory FcRs such as FcγRIII, and inhibited by FcγRII. Enhanced phagocytosis was seen in all mice carrying the AIH (Figure 4) , as it had been in FcγRII-deficient mice [9] . Another measure of macrophage activation is the increase in intracellular calcium that follows cross-linking of FcγRIII on macrophages, which is exaggerated in the macrophages of mice deficient in FcγRII [9] . FcγRs of purified peritoneal macrophages were cross-linked with immune complexes and the resulting intracellular calcium increase was greater in AIH mice than in controls ( Figure 5 ), to a degree comparable to that seen in FcγRII -/-mice [9] . SLE in both humans and lupus-prone mouse strains is associated with polyclonally hyperactive B cells and enhanced immunoglobulin production [13, 16] , consistent with a defect in negative regulation of these cells. Furthermore, targeted deletion of molecules involved in this negative regulation such as Lyn, CD22, FcγRII, SHP-1 and PD-1 predisposes to autoimmune disease in mice [16] [17] [18] . Fcgr2 has been identified as a major candidate gene in different polygenic mouse models as well as in humans with SLE [1] [2] [3] . Our finding that autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of FcγRII strongly suggests that this defect plays a role in the pathogenesis of autoimmune disease. That this haplotype occurs in all the independently derived major mouse models of SLE and the NOD mouse model of diabetes, and not in control mice, suggests the defect in FcγRII makes a profound contribution to the breakdown of tolerance. Other susceptibility genes that differ between the strains presumably lead to manifestation of this tolerance defect as distinct diseases.
SLE is considered an antibody-mediated disease in which much of the tissue damage is initiated by the deposition of immune complexes [13] . In such a disease, a defect in negative regulation of B cells may increase immune complex production. A similar defect in macrophages might increase the inflammatory response to these complexes, and perhaps also antigen presentation, thus contributing to the pathogenesis of disease. In contrast, diabetes in the NOD mouse is thought to be a T-cell-mediated disease. Nonetheless, B cells [19] and macrophages [20] are also required for the development of diabetes, raising the possibility that FcγRII might contribute to its pathogenesis despite being distal to the diabetes susceptibility locus on chromosome 1 [21] .
Similarities in phenotype between the AIH strains might be due to their sharing the FcγRII defect. NZB mice develop haemolytic anaemia and contribute to the development of SLE in the (NZB × NZW) F1 model [13] . Although the major manifestation of autoimmunity in NOD mice is diabetes, they also develop haemolytic anaemia with age [22] and an SLE-like illness can be induced by immunisation with mycobacteria [23] , suggesting a phenotypic overlap between NOD and NZB mice that may be due to their sharing a defect in FcγRII expression. In fact, it has recently been shown that the development of autoantibodies after microbacterial immunisation in NOD mice is linked to a susceptibility interval on distal chromosome 1 similar to those in NZB [10, 11] and BXSB mice [12] (A.G. Baxter, personal communication). These similarities in phenotype might be analogous to 'overlap' syndromes seen in polygenic autoimmune diseases in humans (for example, mixed connective tissue disease), in which shared susceptibility genes contribute to similarities in disease phenotype while others contribute to distinct features.
In summary, we have found that the major mouse models of both SLE and diabetes share a Fcgr2 promoter haplotype. This haplotype is associated with a reduction in the expression and function of the inhibitory FcγRII on macrophages and activated B cells, defects which would be expected to make a substantial contribution to disease pathogenesis. That the haplotype has been selected in these independently derived mouse strains suggests that a defect in FcγRII makes a fundamental contribution to the development of autoimmune disease, with differences between the strains determined by other susceptibility genes, and similarities providing an analogy for autoimmune 'overlap' syndromes.
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Supplementary material
Supplementary material including details of transcription factor binding sites in the Fcgr2 regulatory sequences, the procedure used to identify B cells and macrophages, control experiments showing that the differences between AIH control mice are not due to different levels of activation or proliferation, micrographs of phagocytosis and additional methodological details is available at http://currentbiology.com/supmat/supmatin.htm.
Figure 5
Changes in intracellular Ca 2+ in peritoneal macrophages from AIH and control mice. Peritoneal macrophages were purified by adherence, loaded with the Ca 2+ indicator Indo-1 and FcγRs crosslinked with immune complexes. Changes in FL4/FL5 ratio of the cells was measured by flow cytometry before and after the addition of immune complexes at the point indicated by the arrow. Clear differences in calcium flux are seen between AIH and control mice following addition of (a) immune complexes, but not with the positive controls (b) ionomycin and (c) thapsigargin. Ionomycin permeabilises cell membranes to Ca 2+ and thapsigargin releases Ca 2+ from intracellular stores by inhibiting the endoplasmic reticulum Ca 2+ ATPase, producing FcR-independent Ca 2+ flux. Representative of three experiments, with peritoneal macrophages of two or three mice of each strain pooled in each.
